Aldesleukin

Interleukin 2 (Aldesleukin, Proleukin ) is a major growth factor and activator of cytotoxic and other T-lymphocytes. It is applied in the therapy of metastas-ing renal carcinoma and melanoma. Side effects include... 

When asparaginase is administered to a patient witii diabetes, die risk for hyperglycemia is increased a dosage adjustment of die oral antidiabetic drug may be necessary. Glucocorticoids decrease die effectiveness of aldesleukin. When aldesleukin is administered witii antihypertensive drugs, tiiere is an additive hypotensive effect Etoposide may decrease the immune response to live viral vaccines. 

Proleukin Aldesleukin (interleukin 2) Chiron Renal cell carcinoma, metastatic melanoma... 

Jeal, W. and Goa, K. 1997. Aldesleukin (recombinant interleukin-2) a review of its pharmacological properties, clinical efficacy and tolerability in patients with renal cell carcinoma. Biodrugs 7(4), 285-317. 

Procrit , Epoietin alfa Proleukin, IL-2 Aldesleukin Ortho Biotech, Inc. Chiron... 

Proleukin, IL-2 Aldesleukin Rebetron ribavirin/IFN alfa-2b Chiron Schering-Plough Corp. 

USP received a medication error report involving the products Neumega (oprel-vekin) and Proleukin (aldesleukin). Oprelvekin, a recombinant human interleukin-11 product used to stimulate platelet production in selected patients undergoing chemotherapy, is sometimes abbreviated as IL-11. Aldesleukin, a recombinant human interleukin-2 derivative indicated in designated patient populations for the treatment of metastatic renal-cell carcinoma, is sometimes abbreviated as IL-2. 

In the reported error, a physieian used the abbreviation IL-ll when ordering oprelvekin for a patient. Unfortimately, the order was misinterpreted to be interleukin-2 (i.e., the number eleven was pereeived to be the Roman numeral two). Five or more health eare professionals, ineluding pharmacists and nurses, mistook the order to be aldesleukin. The error was not detected for four days, until it was noted that the inventory of aldesleukin was nearly depleted. 

Drugs that may affect indinavir include didanosine, aldesleukin, anticonvulsants, atazanavir, nelfinavir, nevirapine, omeprazole, rifapentine, ritonavir, clarithromycin, azole antifungals, rifamycins, delavirdine, efavirenz, St. John s wort. 

Drugs that might affect amprenavir include abacavir, aldesleukin, antacids, anticonvulsants, azole antifungals, clarithromycin, cyclosporine, dexamethasone, buffered didanosine, disulfiram, ethanol, indinavir, methadone, metronidazole, nelfinavir, nonnucleoside reverse transcriptase inhibitors, oral contraceptives, rifamycins, ritonavir, saquinavir, St. John s wort, tacrolimus, and zidovudine. 

Immunomodulators affect the functioning of the immune system. Immune functions may be promoted as well as suppressed by these agents. In this section interferon alpha, BCG, immunocyanin and aldesleukine and the monoclonal antibodies, alem-tuzumab, bevacizumab, cetuximab, trastuzumab, rit-uximab and ibritumomab tiuxetan will be briefly discussed. 

Aldesleukin is a recombinant form of human Interleukin-2 (IL-2). It has been approved for the treatment of malignant melanoma and renal cell cancer. The medicine is administered every 8 hours by a 15-minute intravenous infusion for a maximum of 14 doses. Adverse reactions include hypo- and hypertension, gastrointestinal disturbances, fever, fatigue, lethargy, joint pain, headache. Cardiovascular problems may occur. 

Aldesleukin is with recombinant technology prepared interleukin-2 (IL-2). IL-2 binds to the IL-2 receptor and so stimulates proliferation of T-helper cells and cytotoxic T-cells. It also activates macrophages and stimulates B-cell activity. It is used in metastasized renal carcinoma. Life threatening car-diotoxicity may occur. Other adverse effects include bone marrow depression and neurotoxicity with manifestations varying from somnolence to delirium. 

C. Interleukins aldesleukin (interleukin-2, IL-2, Proleukin) Cellular growth factors... 

Aldesleukin (IL-2, Pwleukin) is a human recombinant interleukin-2 protein. Its antitumor action is thought to include multiple effects on the immune system, such as... 

Several serious toxicities have been observed, with a fatahty rate of 5% in the initial studies. The major adverse effect is severe hypotension in as many as 85% of patients, which may lead to myocardial infarctions, pulmonary edema, and strokes. This hypotension is thought to be due to a capillary leak syndrome resulting from extravasation of plasma proteins and fluid into ex-travascular space and a loss of vascular tone. Patients with significant cardiac, pulmonary, renal, hepatic, or CNS conditions should not receive therapy with aldesleukin. Other adverse reactions include nausea and vomiting, diarrhea, stomatitis, anorexia, altered mental status, fevers, and fatigue. 

Dosage form Proleukin is supplied as a sterile, lyophilized cake in single-use vials intended for injection on reconstitution with sterile water for injection. When reconstituted, each ml contains aldesleukin 18 million lU (1.1 mg). 

Pharmacokinetics Aldesleukin displays biphasic pharmacokinetics, with an alpha (distribution) half-life of 13 minutes and a beta (terminal) half-life of 85 minutes. In cancer patients, the mean clearance rate of aldesleukin is 268 ml/min. 

---